Means for obtaining avirulent leishmania promastigotes, promastigotes obtained, and the applications thereof


The invention relates to an expression vector of a gene coding for an antigenic protein of Leishmania promastigote, characterized in that it comprises a PSA gene insert in opposite orientation. The invention can be applied to the development of mutants under-expressing, or no longer expressing, genes coding for an antigenic protein of Leishmania promastigote, and to the therapeutic and/or vaccine-oriented uses thereof.


1. An expression vector for a gene encoding an antigenic leishmania promastigote protein, characterized in that it comprises an insert of an excreted/secreted Promastigote Surface Antigen (PSA) gene in an antisense orientation, wherein said PSA is not gp63. 2. The vector as claimed in claim 1 , characterized in that it contains an L. amazonensis gene insert. 3. The vector as claimed in claim 2 , characterized in that the L. amazonensis gene comprises one of SEQ ID NOs: 1 to 5. 4. The vector as claimed in claim 1 , characterized in that it contains an L. infantum gene insert. 5. The vector as claimed in claim 4 , wherein the vector comprises the nucleotide sequence set forth in SEQ ID NO:6. 6. A genetically modified leishmania promastigote, characterized in that it is an avirulent mutant, transfected with a vector as claimed in claim 1 .
This application is the US national phase of international application PCT/FR2006/000314 filed 10 Feb. 2006, which designated the U.S. and claims benefit of FR 0501348, filed 10 Feb. 2005, the entire contents of each of which are hereby incorporated by reference. The invention relates to means for obtaining avirulent leishmania promastigotes. It also relates to the promastigotes obtained and to the uses thereof, in particular in immunoprophylaxis. Leishmaniases constitute worldwide endemic parasitic infections which represent a considerable public health problem affecting both developing countries and countries such as those of southern Europe, where they are considered to be opportunistic diseases in immuno-depressed individuals. At the current time, no effective immunoprophylactic or immunotherapeutic means exist against leishmaniases , and more particularly against the responsible infectious agent, namely leishmania parasites. Leishmania parasites are flagellate protozoa belonging to the Trypanosomatidae family and to the Leishmania genus. This family includes parasites which can infect humans, and certain animals such as rodents, canines, or mammals. The biological cycle of protozoa of the Leishmania genus is shared between an invertebrate vector host, the sandfly (small hematophagous dipterous insect), and many vertebrates, including humans. The leishmania have a heteroxenous parasitic developmental cycle during which two distinct morphological stages follow on from one another. In the sandfly, the parasite is in a mobile, extracellular, flagellate form inside the digestive tube of the insect, called promastigote stage. In the invertebrate host, the parasite transforms into an immobile ovoid form of from 2 to 6 μm in diameter, with a very short flagellar residue, called amastigote, which will reside in the parasitophorous vacuole, in the cells of the reticulohistiocytic system, mainly macrophages. The female hematophagous vector insect becomes infected via the blood of the contaminated vertebrate host, by ingestion of parasitized macrophages. Most of the ingested amastigotes are then destroyed in the following hours. The survivors transform into promastigotes, which will colonize the median intestine, where they actively multiply. They subsequently migrate to the anterior and buccal parts of the digestive tract and then undergo differentiation leading to the formation of metacyclic promastigotes which are highly infectious for the vertebrate host. The vertebrate host is contaminated with the metacyclic promastigotes when it is bitten by an infected female sandfly. These promastigote forms are injected into the dermis together with saliva, and will then be phagocytized by the cells of the reticulohystiocytic system, in particular macrophages, inside which they differentiate into immobile intracellular amastigote forms. They will then actively multiply by schizogenesis inside the parasitophorous vacuole (phagolysosome) until lysis of the host cell is brought about, thus allowing the released amastigotes to propagate the infection by colonizing other normal macrophages. A further bite by a sandfly will result in infection of the latter and will allow the parasite to perpetuate its cycle. Despite the advances in this field, leishmaniases still remain today a serious public health problem due to the number of individuals involved, the extent of the geographic area covered by the disease, and the diversity and seriousness of the clinical pictures observed. The need for effective vaccines against leishmaniases and for novel therapeutic and/or vaccine-related targets for treating these parasitic diseases can therefore be seen. During infection, the infectious promastigote forms injected into the mammalian host must evade the host's immune response in order to be able to subsequently invade the macrophages. The parasite must therefore implement mechanisms which allow it to escape this immune response and to be capable of adapting to a new environment. Early recognition of the parasite by the host organism during invasion may thus be a key step in resistance to the infection. Surface antigens, lipophosphoglycan (LPG) and gp63 (metalloprotease), also called leishmanolysin, were discovered in the 1980s. LPG is the major surface molecule of the promastigote forms, the role of which as a virulence factor has been confirmed. gp63 is a major surface protease, also considered to be a virulence factor. Antigens of a third type, called PSAs for “Promastigote Surface Antigens”, were discovered in 1988-1989. They constitute the major surface antigens of the promastigote forms. Excretory/secretory antigens (ESAs), which have been very widely studied in many parasitic microorganisms (nematodes, protozoa, etc.), play an important role in the infection and defense mechanisms of these parasites, since they have the possibility of acting remotely. In leishmania , research studies have for a long time been limited by the difficulty in being able to have ESAs available in sufficient amounts to study them. All these antigens appear to play a determining role in the survival and infectiousness of the promastigote forms. Prior studies by the inventor in this field had led to the development of completely defined culture media, without macromolecules and free of fetal calf serum, allowing the continuous culture of the promastigote and amastigote forms under axenic and serum-free conditions. These media, described in particular in patent application FR No. 93 05 779, have made it possible to reproduce, in vitro, the complete parasitic developmental cycle of leishmania , such as L. amazonensis and L. infantum , and to have, under natural conditions, a relatively abundant source of ESAs available by simply concentrating the culture medium supernatant metabolized by the parasites. A characterization of leishmania ESAs could thus be carried out. Studies performed in the inventors, laboratory have thus shown that the major immunogen of the L. amazonensis ESAs has a molecular mass of 45 kDa. The screening of a promastigote-form cDNA expression library with a monoclonal antibody called E2, produced against this major immunogen, has made it possible to isolate and identify cDNA clones encoding proteins of the PSA family. This antibody is produced by the murine hybridoma IV D6/E2 deposited with the C.N.C.M, 28 rue du Dr Roux, Paris, France, on Nov. 10, 2004, under the No. I-3318, more especially by the murine hybridoma deposited on Feb. 3, 2006, with the CNCM under the No. I-3570. Thus, for the first time, three new PSA cDNA sequences expressed in the promastigote form of L. amazonensis were identified. These isolated cDNAs differ from one another by virtue of the number of LRRs (4, 6 or 7). More recently, a screening of an L. infantum promastigote cosmid library has been carried out using, as radiolabeled probe, the DNA encoding L. amazonensis PSA. A new Leishmania gene, IJ11, has been identified, encoding an excreted/secreted protein of L. infantum , of molecular mass 56 kDa (LiPSA 50s), belonging to the PSA family. A functional study of the genes encoding PSAs, major immunogens of the excretory/secretory products of leishmania , was therefore undertaken using the tools provided by genomics. The experimental approach consisted in introducing, into the promastigotes of a leishmania , plasmid constructs capable of inducing a decrease in the level of production of the PSA in order to study the repercussions of these changes on the biology of the parasite and its virulence. It thus appeared that the nondirectional cloning, in an expression vector for the IJ11 gene encoding the LiPSA 50s protein, resulted, after selection, in plasmids being obtained which contain the insert in an antisense orientation (Ldi antisense), allowing the under-expression of the PSA in the modified L. infantum promastigotes. Advantageously, it was found that these results could be generalized both as regards the leishmania species and as regards the gene inserts encoding antigenic proteins that can be used. The aim of the invention is therefore to provide novel expression vector constructs for genes encoding antigenic leishmania promastigote proteins. The invention is also directed toward the use of these constructs for obtaining avirulent leishmania promastigote mutants. According to yet another aspect, the invention is directed toward the uses of these avirulent mutants for immunoprophylactic purposes. The expression vectors according to the invention are characterized in that they contain an insert, in an antisense orientation, of a gene encoding an antigenic leishmania promastigote peptide or protein. Advantageously, the cloning into expression vectors of said genes in an antisense orientation allows the peptide or the protein to be underexpressed in the modified leishmania promastigotes. Preferably, said vectors are characterized in that they contain a leishmania PSA gene insert. In one embodiment of the invention, it is an L. amazonensis gene insert. The L. amazonensis PSA genes are more especially chosen from the group comprising SEQ ID Nos. 1 to 5. In another preferred embodiment of the invention, it is an L. infantum gene insert. The L. infantum genes are advantageously chosen from the group comprising SEQ ID No. 6. The invention is also directed toward genetically modified leishmania promastigotes, characterized in that they are avirulent mutants, transfected with a vector as defined above. The invention is also directed toward a method of obtaining avirulent forms of leishmania promastigotes , characterized in that it comprises: nondirectional insertion, into an expression vector, of genes encoding antigenic leishmania peptides or proteins, selection of the constructs containing the inserts in an antisense orientation, transfection of leishmania promastigote forms using the selected constructs, biological cloning of the genetically transformed promastigotes by micromanipulation so as to obtain mutants which underexpress, or even which no longer express, the gene encoding an antigenic leishmania promastigote protein. The transfection of the promastigote forms is advantageously carried out by electroporation. Revelation of the peptide or of the protein by Western blotting makes it possible to estimate its level of production in the clones. The use of the above arrangements makes it possible to study the consequences of the underexpression of antigenic leishmania peptides or proteins on the behavior of the transformed promastigotes and to thus identify their biological role. To this effect, the various genetically modified parasites were cloned by micromanipulation (biological cloning) and characterized and compared at the molecular level (level of production of the antigenic protein, level of expression of the corresponding transcripts). The phenotypic characterization of the genetically modified and cloned promastigotes consisted in comparing the growth kinetics of these parasites and also their infectious capacity in vitro with respect to canine macrophages. The characterization of a parasitic virulence factor, such as PSA, makes it possible to develop novel strategies for interference with the infectious process for therapeutic and/or vaccine-related purposes. In particular, the invention makes it possible to obtain attenuated, or even avirulent, strains that can be used in animal and/or human vaccination. Other characteristics and advantages of the invention are given in the examples which follow with reference to FIGS. 1 to 4 , which represent, respectively, FIGS. 1 and 2 , the results of analysis by Western blotting of the PSA of total polypeptide extracts of a wild-type strain of Ldi Mon1 and of excretory/secretory antigens of culture supernatants of wild-type strains, of sense and anti-sense transformed parasitic parent strains and of clones thereof; FIG. 3 , results of RT-PCR on transcripts of a gene encoding PSA and of a housekeeping gene; FIG. 4 , the parasitic index determined over the course of the in vitro infection of canine macro-phages with a wild-type strain or clones. MATERIALS AND METHODS I—In Vitro Cultures 1—Axenic Cultures of L. infantum The wild-type strain of Leishmania infantum used in the studies described hereinafter bears the WHO reference: MHOM/MA/67/ITMAP-263/clone2, zymodeme MON-1. The transformed strains were obtained after cloning of the IJ11 gene (1404 bp), encoding the L. infantum PSA (56 kDa), in the sense or antisense position in the expression vector pTEX, and then transfection by electroporation into the promastigote form of L. infantum . The Ldi IJ11 antisense, Ldi pTEX transformed parasites were selected in the presence of increasing concentrations of geneticin up to 50 μg/ml. The presence of the plasmid and the orientation of the transgene (antisense) were verified by Southern blotting and the level of transcription of the transgene was verified by Northern blotting. The promastigote forms are cultured under axenic conditions in a completely defined culture medium containing no macromolecule as serum substitute (serum-free RPMI 199H medium, pH 7), but also in RPMI 1640 medium containing 20% of decomplemented fetal calf serum (20% serum RPMI medium, pH 7.2), and supplemented with penicillin (100 units/ml) and with streptomycin (100 μg/ml). The various transformed strains were cloned by the micromanipulation technique. A single parasite is sampled under a microscope using a fine glass needle and deposited on NNN medium (Novy, macNeal, Nicolle). The culturing of the parasites is carried out by successive subculturings in 20% RPMI medium. The genetically modified promastigote forms and the corresponding clones are maintained in continuous culture by weekly subculturings in serum-containing culture media or adapted in serum-free medium at 25° C. in the presence of geneticin (50 μg/ml). The parasite concentration is determined by flow cytometry (FacsCalibur, Beckton Dickinson). The parasites are conserved by cryofreezing of the organisms in culture in the presence of 3% DMSO (dimethyl sulfoxide) at −180° C. in liquid nitrogen. 2—Macrophage Cultures PBMCs (Peripheral Blood Mononuclear Cells) are isolated from whole blood of a normal dog by Ficoll gradient (Ficoll Lymphoprep®, density 1.077±0.001 g/ml; AbCys, France) and by centrifugation at 700 g for 20 min at ambient temperature. The cells are then washed 3 times in PBS (0.01M phosphate buffered saline, pH 7.2) without Ca 2+ /Mg 2+ by centrifugation at 400 g for 10 min at 4° C., before being resuspended in RPMI 1640 supplemented with 10% of fetal calf serum, 100 units/ml of penicillin and 100 μg/ml of streptomycin, and then cultured at 37° C. II—Harvesting and Preparation of the Parasite Material 1—Harvesting of the Parasite Material The promastigote forms in the stationary growth phase (7 days) are harvested by centrifugation of the serum-free parasite cultures at 3000 g for 10 min at 4° C. The parasite pellets and the culture supernatants thus dissociated are then treated separately. 2—Preparation of Parasite Lysates The parasite pellet is washed twice in PBS under the centrifugation conditions described above. After the final wash, the number of parasites harvested is determined by flow cytometry. 10 9 washed parasites are resuspended in a hypotonic lysis solution: 50 mM Tris, pH 8, containing 1% of Triton X100 (Sigma). After incubation at 4° C. for 20 min, centrifugation for 20 min at 4° C. and at 2000 g makes it possible to separate the insoluble material (debris) from the supernatant (soluble molecules). This supernatant corresponds to a total polypeptide extract (TPE). 3—Concentration of the Excretory/Secretory Antigens (ESAs) from the Culture Supernatant Metabolized by the Parasites 10 ml of supernatant metabolized by the parasites are filtered through a Millipore membrane (0.22 μm) and then frozen in shells before being freeze-dried. The freeze-dried materials are taken up in 1 ml of milliQ water in order to be dialyzed for 48 h at 4° C. so as to remove the salts. A second freeze-drying process makes it possible to concentrate the supernatant 200-fold. III—Biochemical Analyses 1—Protein Assay The assaying of the proteins is carried out using the Beckman DU-600 spectrophotometer, at 595 nm, according to the Bradford method, using the Biorad reagent (Biorad Protein Assay Kit 11). A standard range, from 5 to 20 μg/ml, is prepared from a standard bovine albumin solution (1 mg/ml BSA, Sigma). 2—SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis) Analysis The SDS-PAGE polyacrylamide gel analysis was carried out in a mini-gel electrophoresis tank (Biorad). The acrylamide percentages used are 5% for the stacking gel and 10% for the separating gel, thereby making it possible to separate proteins of 10 to 200 kDa. TPE protein concentrations are mixed (v/v) with sample buffer containing 4% SDS, 20% glycerol and 0.5% bromo-phenol blue in 0.5M Tris-HCl, pH 6.8. The electrophoretic migration is carried out in a buffer (2.5 mM Tris/19.2 mM glycine, pH 8.3) containing 0.1% SDS under a constant voltage of 80V. The calibration of the gel is obtained by depositing 10 μg of standard proteins of known molecular weights (Mark12 Wide Range Protein Standard/SeeBlue® Plus2 Pre-Stained Standard, Novex). 3—Revelation of the Proteins with Silver Nitrate After removal of the SDS by washing in the presence of acetic acid (10%) and ethanol (40%) for 1 h, the acetic acid is then itself removed by two rinses for 30 min in 50% ethanol. The gels are then incubated for 15 min in a staining mixture: 19.4% AgNO 3 -0.36% NaOH. After 5 washes in milliQ water, a revealing solution containing 0.02% formaldehyde in 1% citric acid (w/v) reveals the proteins on the gel. The revelation threshold for this staining method is 2 ng of protein equivalent. IV—Immunoanalyses 1—Western Blotting After having been separated in an SDS-PAGE polyacrylamide gel, the proteins are blotted onto a nitrocellulose membrane (Amersham, Hybond-C Extra). The blotting is carried out under semi-dry conditions. The membranes are then saturated for one hour in a TBS-5% milk blocking solution. The membranes are incubated overnight at ambient temperature and with agitation, with the F5 monoclonal antibody directed against PSA and obtained in mice (MAB F5), diluted to 1/50 in TBS. After 3 washes for 5 min in TBS, the bound antibodies are detected with peroxidase-coupled anti-mouse immuno-globulin G secondary antibodies (Tebu) diluted to 1/500 in TBS and incubated for 45 min at ambient temperature with agitation. Next, 3 washes for 5 min in TBS are carried out before revealing the reaction with a solution containing 15 mg of 4-chloro-1-naphthol dissolved in 5 ml of methanol, to which are added 25 ml of TBS containing 15 μl of 30% H 2 O 2 . The reaction is stopped by washing the membrane with distilled water. 2—Indirect Immunofluorescence on Parasites The parasites in the stationary phase of their culture (7 days) are fixed with 1% formaldehyde in PBS without Ca 2+ /Mg 2+ , and then washed. Once fixed, the parasites are deposited on Teflon-coated wells (10 wells, 50 ml/well) and dried in the open air. Each well is then processed with the F5 monoclonal antibody (MAB F5) diluted in a (saturating) blocking solution (1% goat serum, 0.5% BSA in PBS) for 30 min at 37° C. The cells are then washed and incubated for 30 min at 37° C. with the second antibody conjugated to fluorescein isothio-cyanate (FITC) (goat anti-mouse immunoglobulin G anti-serum) diluted to 1/300 in a solution of PBS containing Evans blue at 1/7500. The slides are observed under a photon fluorescence microscope (Leitz). V—Molecular Analysis 1—Total RNA Extraction The promastigote forms are harvested by centrifugation of the serum-free parasite cultures at 3000 g for 10 min at 4° C. The parasite pellet is washed twice in PBS under the above centrifugation conditions. After the final wash, in order to lyse the parasites and to inhibit the endogenous ribonucleases (RNAses), the cells are dissociated by vortexing in 1 ml of Trizol (Trizol Reagent, GibcoBRL), and then incubated for 5 min at ambient temperature. The lysate is incubated in 0.2 ml of chloroform for 2 min at ambient temperature, and then centrifuged at 12,000 g for 15 min at 4° C. so as to give two phases, an aqueous phase and an organic phase. The RNAs are exclusively in the aqueous phase, which is recovered. The RNAs are then precipitated by adding 0.5 ml of isopropanol and incubated for 10 min at ambient temperature, and then centrifuged at 12,000 g for 10 min at 4° C. The pellet is washed in 1 ml of 75% ethanol, and then centrifuged at 7500 g for 5 min at 4° C., before being taken up in 40 μl of water (RNAse-free). In order to remove any possible presence of DNA, the dissolved RNA pellet is taken up in 1 μl of DNAse I+0.1 volume of 10×DNAse I buffer, and incubated for 20 min at 37° C. After the addition of 5 μl of DNAse inactivation reagent, incubation for 2 min at ambient temperature and then centrifugation at 10,000 g for 1 min at 4° C., the supernatant containing the RNAs is recovered. The total RNA is quantified by spectrophotometry, the absorbance being read at 260 nm (1 OD unit=40 μg/ml of single-stranded RNA). The quality of the extracted RNA and the amount and the size are verified by electrophoresis on 1% agarose gel in 0.5×TAE buffer, in the presence of 0.01% ethidium bromide (ETB). The size marker used is the SmartLadder (Eurogentec). The total RNA is then visualized under UV at 312 nm after migration. The selected criteria for quality of the extraction are the absence of DNA and the visualization of 3 ribosomal RNA bands of equal intensity. 2—RT-PCR The single-stranded cDNA is synthesized by carrying out an RT-PCR with 1 μg of total RNA, 2 μl of dNTP mix (5 mM), 0.2 μl of specific primers (10 μM) and H 2 O qs 13 μl. The mix is incubated for 2 min at 65° C. and then for 2 min in ice, before the following are added: 4 μl of 5× buffer, 1 μl of DTT (0.1M), 1 μl of Superase In (40U) (RNAse Inhibitor, Ambion) and 1 μl of SuperScript™ (200U) (Reverse Transcriptase, Invitrogen). The mix is incubated for 50 min at 42° C., and the reaction is then inactivated by heat shock for 15 min at 70° C. The single-stranded cDNA is amplified by PCR with 3 μl of cDNA, 12.5 μl of PCR Mastermix (Promega), 1 μl of 5′P and 3′P specific primers (10 μM) and H 2 O qs 25 μl. The following primers were used: SEQ ID No. 7 -nhinsp1: 5′-CATCGCTTACCCCTTGTT-3′ SEQ ID No. 8 -nhinsp2: 5′-GTGGCCAATCGCGACA-3′ SEQ ID No. 9 -P1RT: 5′-ATGGCGCTGTGCGTGCGTCGG-3′ SEQ ID No. 10 -P4RT: 5′-GCGCGCGACAGCAGCGGCAT-3′. The program of the PCR reaction used and carried out in a thermocycler (GeneAmp PCR System 2400, Applied Biosystems) is the following: 5 min at 94° C., then 27 cycles (94° C. 30 sec, 55° C. 1 min, 72° C. 1 min) and 10 min at 72° C. The PCR products are verified by 1% agarose gel electrophoresis. VI—Biological Analysis 1—Growth Kinetics The in vitro culture kinetics were realized over 10 days in RPMI 20% medium, starting from an initial concentration of 5×10 5 parasites/ml. The parasite concentration is determined by flow cytometry (FacsCalibur, Beckton Dickinson), by mixing 500 μl of PBS, 5 μl of culture and 0.5 μl of propidium iodide. 2—In Vitro Infection in Parasite/Macrophage Interactions 10 6 PBMCs/well (200 μl), isolated from normal dog whole blood, are distributed in LabTek® culture chambers (Nalge Nunc International). After incubation for 30 min at 37° C., 5% CO 2 , the LabTek® are washed gently with RPMI 10% in order to remove the cells which have not adhered. The macrophages are obtained from the cultured monocytes after 5 days of maturation. The mature macrophages are infected in vitro with promastigote forms in the stationary culture phase, for 30 min, 2 h and 48 h at 37° C. and 5% CO 2 at a parasite:macrophage ratio of 10:1. The macrophages are then washed gently twice in order to remove the nonphagocytozed parasites. After 30 min, 2 h and 48 h, the cells are fixed with methanol and stained with Giemsa. 300 macrophages are observed under an immersion optical microscope (1000× magnification), and the percentage of parasitized macrophages, the number of amastigotes per macrophage and the parasitic index (P.I.) are determined. The P.I. is equivalent to the percentage of infected macrophages multiplied by the number of amastigotes per macrophage. Results Evaluation of the Level of Production of PSA in the Transformed Clones FIGS. 1 and 2 report the results of Western blotting analysis of the PSA, respectively, of total polypeptide extracts (TPE) derived from the parasite pellets of the wild-type strain Ldi Mon1, on excretory/secretory antigens (ESAs) derived from metabolized culture medium supernatants of the wild-type strain Ldi Mon1, of the parent strains of transformed parasites (Ldi pTEX, Ldi IJ11 sense and Ldi IJ11 antisense) and of their corresponding clones (5 μg protein equivalent of total extract per lane). It is noted that no band is observed for the wild-type strain Ldi Mon1, that the overexpression is, on the other hand, clearly visible for Ldi IJ11 sense, both at the level of the TPEs and the ESAs, compared with the expression in Ldi pTEX, and that a decrease in the expression of the PSA is observed with Ldi IJ11 antisense. Analysis of the PSA Transcripts by RT-PCR An RT-PCR was carried out on the transcripts of the gene encoding the PSA and also on the transcripts of a housekeeping gene encoding nucleoside hydrolase. The results obtained are given in FIG. 3 . A significant increase in the level of the transcripts encoding the PSA is observed in Ldi IJ11 sense, and a notable decrease is observed in Ldi IJ11 antisense, compared with Ldi pTEX. No signal is observed with the wild-type strain of Ldi Mon1. In Vitro Infectious Capacity in the Parasite-Macrophage Interactions FIG. 4 reports the parasitic index determined during the in vitro infection of canine macrophages with the wild-type strain or the various selected clones at various incubation times: 30 min (parasite attachment to the macrophages), 2 h (parasite penetration) and 48 h (survival and multiplication of amastigotes). It is noted that, at 30 min and at 2 h, the Ldi IJ11 sense promastigotes exhibit a parasitic index which is approximately two times higher than those of Ldi IJ11 antisense is approximately two times lower. The same results are obtained after 48 h of infection. VII—Study of the In Vivo Role of the pTEX, Sense and Antisense Mutant Infection of Balb/C Mice by IP Injection with 10 8 Promastigotes/100 μl Protocol for Measuring Parasitemia (Parasite Burdens) BIBLIOGRAPHIC REFERENCE P. A. Buffet et al., 1995 . Antimicrobial agents and chemotherapy. Vol. 39: 2167-2168 Prepare: 1 tube of 15 ml per organ with 4 ml of SDM or RPMI medium/20% FCS Weigh the tubes+medium (weight=T in g) Cell Strainer+small Petri dishes (1 cell strainer for two same organs belonging to the same group/batch of mice)+1 ml syringe On spleen and liver organs: For the spleen: remove the entire spleen For the liver: remove only the small lobe Weighing of organs (organ in tube+medium, weight=TO in g) Grinding/homogenization with a Potter homogenizer or cell strainer in 4 ml of medium. For parasitemia/spleen: In a 96-well plate, remove 250 μl of cells for the 1st well and prepare doubling dilutions with 150 μl of parasites in 150 μl of medium, and then, for the following wells, remove 150 μl to be diluted in 150 μl of medium, etc. Prepare 2×12 wells of dilutions (2 rows). After incubation for 7 and 15 days at 26-28° C., the plates are examined under an inverted microscope (×100 or ×200 objective). Note the absence or the presence of parasites for each well. Note the last well where parasites are present. For parasitemia/liver: In a 96-well plate, remove 25 μl of cells for the 1st well containing 225 μl of medium and prepare 4-fold serial dilutions with 50 μl of parasites in 150 μl of medium, and then, for the following wells, remove 50 μl to be diluted in 150 μl of medium, etc. Prepare 2×12 wells of dilutions (2 rows). After incubation for 7 and 15 days at 26-28° C., the plates are examined under an inverted microscope (×100 or ×200 objective). Note the absence or the presence of parasites for each well. Note the last well where parasites are present. The final titer corresponds to the last dilution for which the well contains at least 1 parasite. The number of parasites per gram (parasite burden) in the corresponding organ is calculated in the following way: Number of parasites=(geometric mean of the inverse titers of each duplicate/weight of section homogenized)×400 Parasite ⁢ ⁢ burden = inverse ⁢ ⁢ of ⁢ ⁢ the ⁢ ⁢ limiting ⁢ ⁢ dilution organ ⁢ ⁢ weight ⁢ ⁢ ( g ) × 400 N.B.:—400 corresponds to the inverse fraction of the homogenized organ inoculated in the 1st well <10 3 to >10 6 Point at 14 days after infection: Parasitemia (reading at 15 days) carried out in duplicate and doubling dilutions Parasite burden=(inverse of the limiting dilution/organ weight (g))×400 General Organ Parasite Mean mean weight Limiting burden Parasite Standard Parasite Standard (g) dilution Parasite g-1 burden deviation burden deviation g Batch 1 pTEX Mouse 1 spleen 0.14 0.0078 366300 274725 129507 107912 56756 without mouse 1 trial 0.14 0.0156 183150 183150 Mouse 2 spleen 0.16 0.0156 160256 120064 56840 without mouse 1 trial 0.16 0.0313 79872 67348 22927 1 and 2 and Mouse 3 spleen 0.14 0.0625 45714 68498 32222 without mouse 2 trial 0.14 0.0313 91283 Mouse 4 spleen 0.16 0.0625 40000 59936 28194 0.16 0.0313 79872 Batch 2 sense Mouse 1 spleen 0.14 0.5 5714 2857 4041 2367 1517 0.14 nothing 0 Mouse 2 spleen 0.19 nothing 0 2105 2977 0.19 0.5 4211 Mouse 3 spleen 0.24 1 1667 833 1179 0.24 nothing 0 Mouse 4 spleen 0.17 0.25 9412 7059 3328 0.17 0.5 4706 4706 Mouse 5 spleen 0.15 1 2667 1333 1886 0.15 nothing 0 Batch 3 antisense Mouse 1 spleen 0.13 0.25 12308 12308 0 8744 2458 0.13 0.25 12308 Mouse 2 spleen 0.14 1 2857 1429 2020 0.14 nothing 0 Mouse 3 spleen 0.15 0.5 5333 8000 3771 0.15 0.25 10667 Mouse 4 spleen 0.18 0.25 8889 6667 3143 0.18 0.5 4444 Mouse 5 spleen 0.20 0.25 8000 8000 0 0.20 0.25 8000 results in red not taken into account Summary point 15 d Mean Parasite Standard Mean burden deviation deviation Batch 1 pTEX Mouse 1 spleen 274725 129507 91575 Mouse 2 spleen 120064 56840 40192 Mouse 3 spleen 68498 32222 22784 Mouse 4 spleen 59936 28194 19936 Batch 2 sense Mouse 1 spleen 2857 4041 2857 Mouse 2 spleen 2105 2977 2105 Mouse 3 spleen 833 1179 833 Mouse 4 spleen 7059 3328 2353 Mouse 5 spleen 1333 1886 1333 Batch 3 antisense Mouse 1 spleen 12308 0 0 Mouse 2 spleen 1429 2020 1429 Mouse 3 spleen 8000 3771 2667 Mouse 4 spleen 6667 3143 2222 Mouse 5 spleen 8000 0 0 Mean Parasite Standard burden deviation pTEX mouse 2 spleen 120064 56840 pTEX mouse 3 spleen 68498 32222 pTEX mouse 4 spleen 59936 28194 Sense mouse 1 spleen 2857 4041 Sense mouse 2 spleen 2105 2977 Sense mouse 3 spleen 833 1179 Sense mouse 4 spleen 7059 3328 Sense mouse 5 spleen 1333 1886 Antisense mouse 1 spleen 12308 0 Antisense mouse 2 spleen 1429 2020 Antisense mouse 3 spleen 8000 3771 Antisense mouse 4 spleen 6667 3143 Antisense mouse 5 spleen 8000 0 Parasite Standard burden deviation pTEX 82833 3252 Sense 2838 248 Antisense 7281 390 Parasitemia (2 months) Parasite General Organ burden Mean mean Standard weight Limiting parasite Parasite Parasite deviation SPLEEN (g) dilution g-1 burden burden g Batch 1 pTEX Mouse 1 spleen 0.14 0.016 182857 264127 118470 Mouse 2 spleen 0.14 0.008 365714 Mouse 3 spleen 0.17 0.031 75294 Mouse 4 spleen 0.18 0.016 142222 Mouse 5 spleen 0.14 0.008 365714 Batch 2 sense Mouse 1 spleen 0.1 NI 0 0 0 Mouse 2 spleen 0.15 NI 0 Mouse 3 spleen 0.12 NI 0 Mouse 4 spleen 0.14 NI 0 Mouse 5 spleen 0.14 NI 0 Batch 3 antisense Mouse 1 spleen 0.11 NI 0 1813 2914 Mouse 2 spleen 0.12    0.500 6667 Mouse 3 spleen 0.19   0.500 4211 Mouse 4 spleen 0.13 NI 0 Mouse 5 spleen 0.14 NI 0 Mouse 6 spleen 0.18 NI 0 Parasite burden g-1 Standard deviation Spleen 15 days 2 months 15 days 2 months pTEX 107912 264127 56756 118470 Sense 2367 0 1517 0 Antisense 8744 1813 2458 2914 pTEX 67348 264127 22927 118470 Sense 2367 0 1517 0 Antisense 8744 1813 2458 2914 results in red not taken into account NI = non infected Parasitemia (2 months) Organ Parasite weight Limiting burden LIVER (g) dilution parasite g-1 Batch 1 pTEX 2495238 4025557 with mouse 1 Mouse 1 liver 0.12 0.000391 8533333 Mouse 2 liver 0.1 0.000024 163840000 482540 43989 without mouse 1 Mouse 3 liver 0.14 0.006250 457143 Mouse 4 liver 0.14 0.006250 457143 Mouse 5 liver 0.12 0.006250 533333 Batch 2 sense Mouse 1 liver 0.17 NI 0 0 0 Mouse 2 liver 0.18 NI 0 Mouse 3 liver 0.12 NI 0 Mouse 4 liver 0.14? NI 0 Mouse 5 liver 0.09 NI 0 Batch 3 antisense Mouse 1 liver 0.12 NI 0 38889 61162 Mouse 2 liver 0.16 0.025 100000 Mouse 3 liver 0.1 NI 0 Mouse 4 liver 0.08 NI 0 Mouse 5 liver 0.12 0.025 133333 Mouse 6 liver 0.1 NI 0



Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    US-2002169285-A1November 14, 2002Reed Steven G., Antonio Campos-Neto, Webb John R., Dillon David C.Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
    US-2003068690-A1April 10, 2003Institut Francais De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom)Process for the in vitro culture of different stages of tissular parasites
    US-2003157125-A1August 21, 2003Alvarez Manuel Soto, Bedate Carlos Alonso, Requena Rolania Jose MariaComposition containing leishmania lip2a
    US-2008026467-A1January 31, 2008Jean-Loup Lemesre, Mireille Cavaleyra, Denis Sereno, Philippe HolzmullerNovel Agents for the Prevention of Leishmaniosis
    WO-9426899-A1November 24, 1994Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom)Procede de culture in vitro de differents stades de parasites tissulaires

NO-Patent Citations (17)

    Beetham et al., Glycoprotein 46 mRNA abundance is post-transcriptionally regulated during development of Leishmania chagasi promastigotes to an infectious form, Journal of Biological Chemistry, vol. 272, No. 28, 1997, pp. 17360-17366, XP002296788.
    Beverley et al., "Flypaper for Parasites," Cell, vol. 119, Oct. 29, 2004, pp. 311-316, XP009051110.
    Breitlow, "Selection of protein stains for SDS gel electrophoresis", Promega Notes Magazine No. 35, Feb. 1992.
    Chen et al., "Episomal Expression of Specific Sense and Antisense MRNAs in Leishmania Amazonensis: Modulation of GP63 Level in Promatigotes and their Infection of Macrophages in Vitro," Infection and Immunity, vol. 68, No. 1, 2000, 1980 p. 86, XP009051114.
    Dumonteil et al., DNA vaccines induce partial protection against Leishmania mexicana, Vaccine, vol. 21, No. 17-18, May 16, 2003, pp. 2170-2177, XP004421134.
    Hajmova et al., "Down Regulation of GP63 in Leishmania Amazonensis Reduces its Early Development in Lutzomyia Longialpis," Microbes and Infection, vol. 6, 2004, pp. 646-649, XP009051117.
    Handman et al., Therapy of murine cutaneous leishmaniasis by DNA vaccination, Vaccine, vol. 18, No. 26, Jul. 2000, pp. 3011-3017, XP004199096.
    International Search Report for PCT/FR04/02955 dated Aug. 17, 2005.
    International Search Report for PCT/FR2006/000314 mailed Jun. 21, 2006 (English and French).
    Jimenez-Ruiz et al., Cloning Sequencing and Expression of the PSA Genes from Leishmania infantum, European Journal of Biochemistry, vol. 251, No. 1 / 2, Jan. 15, 1998, pp. 389-397, XP001159173.
    Joshi et al., "Targeted Gene Deletion in Leishmania Major Identifies Leishmanolysin (GP63) as a Virulence Factor," Molecular and Biochemical Parasitology, vol. 120, 2002, pp. 33-40, XP009051113.
    Kima et al., Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous leishmanial antigen to CD8+ T cells, Journal of Immunology, Aug. 15, 1997, vol. 159, No. 4, pp. 1828-1834, XP002336360.
    Lebowitz et al., Development of a Stable Leishmania Expression Vector and Application to the Study of Parasite Surface Antigen Genes, Proceedings of the National Academy of Science, vol. 87, Dec. 1990, pp. 9736-9740, XP002052133.
    Loman et al., Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis, Proceedings of the National Academy of Sciences of USA, vol. 87, Nov. 1990, pp. 8393-8397, XP002204079.
    Murray et al., Variants of a Leishmania Surface Antigen Derived from a Multigenic Family, Journal of Biological Chemistry, vol. 266, No. 36, 1991, pp. 24477-24484, XP002296789.
    Shreffler et al (Journal of Infectious Diseases, vol. 167, No. 2, pp. 426-430, 1993).
    Symons et al., Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species, Molecular and Biochemical Parasitology, vol. 67, No. 1, 1994, pp. 103-113, XP002336361.

Cited By (0)

    Publication numberPublication dateAssigneeTitle